Relay Therapeutics (RLAY) EBITDA Margin (2021 - 2026)
Relay Therapeutics (RLAY) reported EBITDA Margin of 2448.77% for Q1 2026, down 145859.0% year-over-year from N/an in Q1 2025, and down 213.66% on a QoQ basis from 780.71% in Q4 2025.
Relay Therapeutics (RLAY) has 6 years of EBITDA Margin data on file, last reported at 2448.77% in Q1 2026.
- Quarterly EBITDA Margin fell 145859.0% year-over-year to 2448.77% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2549.24% (up 177672.0% YoY) and the FY2025 annual result came in at 1789.35%, up 159331.0% from the prior year.
- EBITDA Margin declined to 2448.77% in Q1 2026 per RLAY's latest filing, from 780.71% in the prior quarter.
- Across five years, EBITDA Margin topped out at 8030500.0% in Q4 2023 and bottomed at 83011.76% in Q2 2023.
- The 5-year median for EBITDA Margin is 10424.82% (2025), against an average of 600245.04%.
- Peak annual rise in EBITDA Margin reached 805600751 bps in 2023, while the deepest fall reached 6123752 bps in 2023.
- Tracing RLAY's EBITDA Margin over 5 years: stood at 25507.51% in 2022, then surged by 31583 bps to 8030500.0% in 2023, then slumped by 100 bps to 822.91% in 2024, then gained by 5 bps to 780.71% in 2025, then plunged by 214 bps to 2448.77% in 2026.
- Per Business Quant, the three latest RLAY EBITDA Margin figures stand at 2448.77% (Q1 2026), 780.71% (Q4 2025), and 10424.82% (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | Relay Therapeutics | 2.53 Bn | 2.53 Bn | - | -2,448.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,448.77% |
| Dec 31, 2025 | -780.71% |
| Jun 30, 2025 | -10,424.82% |
| Mar 31, 2025 | -990.18% |
| Mar 31, 2024 | -822.91% |
| Dec 31, 2023 | 8,030,500.00% |
| Sep 30, 2023 | -250.13% |
| Jun 30, 2023 | -83,011.76% |
| Mar 31, 2023 | -39,655.31% |
| Dec 31, 2022 | -25,507.51% |
| Sep 30, 2022 | -24,899.71% |
| Jun 30, 2022 | -21,774.25% |
| Mar 31, 2022 | -16,748.45% |
| Dec 31, 2021 | -12,090.65% |
| Sep 30, 2021 | -9,122.97% |
| Jun 30, 2021 | -22,923.58% |
| Mar 31, 2021 | -4,436.55% |